Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors

• Published in: Antiviral research 2002-06, Vol.54 (3), p.143-147
• Main Authors: Boivin, Guy, Goyette, Nathalie
• Format: Article
• Language: English
• Subjects: Acetamides - pharmacology; Antibiotics. Antiinfectious agents. Antiparasitic agents; Antiviral agents; BCX-1812; Biological and medical sciences; Canada; Cyclopentanes - pharmacology; Drug Resistance, Viral; Enzyme Inhibitors - pharmacology; Fluorometry; Guanidines; Humans; Influenza A; Influenza A virus; Influenza A virus - drug effects; Influenza A virus - enzymology; Influenza B; Influenza B virus; Influenza B virus - drug effects; Influenza B virus - enzymology; Influenza, Human - drug therapy; Inhibitors; Inhibitory Concentration 50; Luminescent Measurements; Medical sciences; Neuraminidase - antagonists & inhibitors; Oseltamivir; oseltamivir carboxylate; Pharmacology. Drug treatments; Pyrans; RWJ-270201; Sialic Acids - pharmacology; Virus; Zanamivir
• ISSN: 0166-3542; 1872-9096
• DOI: 10.1016/S0166-3542(01)00219-4

Forty-two influenza A and 23 influenza B isolates collected from untreated subjects during the 1999–2000 influenza season in Canada were tested for their susceptibility to three neuraminidase inhibitors (zanamivir, oseltamivir carboxylate and RWJ-270201 or BCX-1812) using a chemiluminescent neuraminidase assay. Influenza B isolates were less susceptible than A viruses to all tested drugs. RWJ-270201 was the most potent drug against both influenza A(H3N2) (mean IC 50: 0.60 nM) and B (mean IC 50: 0.87 nM) viruses. Oseltamivir carboxylate was more active than zanamivir for influenza A(H3N2) isolates (mean IC 50: 0.73 vs. 2.09 nM) whereas it was less potent against B viruses (mean IC 50: 11.53 vs. 4.15 nM).